Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: J Immunother. 2018 Jun;41(5):241–247. doi: 10.1097/CJI.0000000000000223

Table 3.

Overall responses in 144 patients treated with tumor infiltrating lymphocytes.*

Outcome Stage M1c - no brain metastases (n=111) Stage M1c - treated brain metastases (n=15) Stage M1c - untreated brain metastases (n=18)
Progressive disease 56 (50%) 10 (67%) 12 (67%)
Stable disease 1 (1%) 0 (0%) 0 (0%)
Partial response 31 (28%) 4 (26%) 6 (33%)
 Ongoing 10 1 1
Complete response 23 (21%) 1 (7%) 0 (0%)
 Ongoing 22 0 0
*

by RECIST criteria